1 University of Hawaii Daniel K. Inouye College of Pharmacy, Hilo.
3 UC Davis Health System, Sacamento, California.
J Manag Care Spec Pharm. 2018 May;24(5):423-429. doi: 10.18553/jmcp.2018.24.5.423.
Clinical pharmacy services were initiated at 7 of 11 clinics within a primary care network (PCN), which was designated as a patient-centered medical home and was affiliated with a large academic medical center in October 2014. The goal of the service was to target patients with uncontrolled chronic conditions, specifically diabetes. Patients met with a clinical pharmacist through individual clinic and telephonic appointments, in addition to usual appointments with physicians as needed. While managing patients with diabetes, many clinicians assess a patient's hemoglobin A1c (A1c), along with blood pressure and cholesterol, as indicators of disease state control and cardiovascular risk. These 3 parameters were combined into a bundled response score (BRS) in order to assess whether the addition of the clinical pharmacy service had a positive effect on patient therapeutic goal attainment rates for these areas.
To assess the effect of pharmacist-led comprehensive medication management (CMM) on therapeutic goal attainment rates for glycemic, blood pressure, and dyslipidemia outcomes in PCN patients, which was represented by a BRS based on how many therapeutic goals were met.
This retrospective study was conducted using patients seen in clinics within the PCN between October 1, 2014, and October 31, 2015. Patients were included in the intervention group if they were actively managed by a PCN pharmacist and had a diagnosis of diabetes. A control group included patients without access to a PCN pharmacist and was matched to the intervention group by baseline A1c results. Based on current clinical practice guidelines, therapeutic goals for the BRS were set as A1c ≤ 8%, blood pressure ≤ 140/90 mmHg, and prescription of a moderate- to high-intensity statin for dyslipidemia. In addition to the primary outcome, the individual components of the BRS were assessed, as well as the average number of medications used between groups.
There were 95 patients included in the intervention group, with 132 patients included in the usual care group. Patients in the intervention group had significantly higher rates of therapeutic goal attainment for the 3 endpoints (40% vs. 12%, P < 0.001). The intervention group had statistically significantly higher improvements in the individual areas of A1c, blood pressure, and statin goal attainment. There were no significant differences in the number of medications for diabetes or antihypertensive medications used between groups at the time of study termination.
This study demonstrated that the addition of CMM services provided by clinical pharmacists in this PCN had a positive effect on therapeutic goal attainment rates for patients with diabetes. This finding suggests that the integration of clinical pharmacists into primary care clinics could have positive effects on the clinical outcomes of diabetic patients in glycemic control, blood pressure, and statin treatment, in accordance with current guidelines.
Support for this study was provided to Wilson by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number ULI TR001860. The content of this article is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health. The authors have nothing additional to disclose.
临床药学服务始于 2014 年 10 月在一个基础医疗保健网络(PCN)的 11 个诊所中的 7 个诊所中启动,该网络被指定为以患者为中心的医疗之家,并与一家大型学术医疗中心有关联。该服务的目标是针对慢性疾病控制不佳的患者,特别是糖尿病患者。患者通过个人诊所和电话预约与临床药师会面,同时根据需要与医生进行常规预约。在管理糖尿病患者时,许多临床医生会评估患者的血红蛋白 A1c(A1c)、血压和胆固醇,以作为疾病控制和心血管风险的指标。为了评估临床药师服务的加入对这些领域的患者治疗目标达标率是否有积极影响,这 3 个参数被合并为一个综合反应评分(BRS)。
评估药师主导的综合药物管理(CMM)对 PCN 患者血糖、血压和血脂异常治疗目标达标率的影响,这是基于满足多少治疗目标的 BRS 来表示的。
这项回顾性研究使用了 2014 年 10 月 1 日至 2015 年 10 月 31 日期间在 PCN 诊所就诊的患者。如果患者正在接受 PCN 药剂师的积极管理,且患有糖尿病,则将其纳入干预组。对照组包括未获得 PCN 药剂师服务的患者,并根据基线 A1c 结果与干预组相匹配。根据当前临床实践指南,BRS 的治疗目标设定为 A1c≤8%、血压≤140/90mmHg 和开具中高强度他汀类药物治疗血脂异常。除了主要结局外,还评估了 BRS 的各个组成部分以及两组之间的平均用药数量。
干预组有 95 例患者,常规护理组有 132 例患者。干预组在 3 个终点上的治疗目标达标率显著更高(40%比 12%,P<0.001)。干预组在 A1c、血压和他汀类药物目标达标方面的个体领域均有统计学显著改善。在研究结束时,两组用于糖尿病或抗高血压药物的药物数量没有显著差异。
这项研究表明,在这个 PCN 中提供的 CMM 服务临床药师的加入对糖尿病患者的治疗目标达标率有积极影响。这一发现表明,临床药师整合到基层医疗诊所可能会对符合当前指南的糖尿病患者的血糖控制、血压和他汀类药物治疗的临床结局产生积极影响。
这项研究得到了美国国立卫生研究院国家转化医学促进中心的支持,资助编号为 ULI TR001860。本文内容仅为作者的责任,不一定代表美国国立卫生研究院的观点。作者没有其他需要披露的内容。